---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-24-000159"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:39:59.876354+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcus Q3 net loss $92M; casdatifan shows 34% ORR, domvanalimab 36% risk reduction

## Summary
- Net loss $92M vs $71M YoY; revenue $48M (up from $32M) on $41M license and development services.
- Cash, equivalents and securities $1.1B, providing runway into mid-2027; year-end expected $950M-$985M.
- Casdatifan 100mg cohort: 34% ORR (25% confirmed), 19% primary progression, median PFS not reached.
- Domvanalimab+zimberelimab reduced risk of death by 36% (HR=0.64) vs zim in 1L NSCLC; median OS not reached.
- Clinical collaboration with AstraZeneca to test casdatifan + volrustomig in IO-naive ccRCC.

## SEC filing metadata
- accession: 0001724521-24-000159
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000159/0001724521-24-000159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000159/rcus-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-24-000159
- JSON: https://secwatch.observer/filing/0001724521-24-000159.json
- Plain text: https://secwatch.observer/filing/0001724521-24-000159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.